Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06458712 as recruiting, last updated 2026-09-02. Enrolment is 180 planned participants, an estimate. Interventions: DSB2455. Primary measures include Number of patients demonstrating dose limiting toxicities and SAEs; Number of patients exhibiting reduction in tumor size.. No results are posted in the registry; this does not exclude separate publications.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types), Prostate cancer.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Prostate cancer.
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/